Denali Therapeutics opened lower at $19.39, compared with its previous close of $19.73. In the last trading session, the stock traded between $18.80 and $19.60. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Denali Therapeutics is now worth
$ 36.97
Resulting in a loss of
$ 63.03 (63.03%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.85 (-4.28%)
Day High
$19.60
Day Low
$18.80
Day Open
$19.39
Prev Close
$19.73
Volume
9,56,477
1W Return
-9.85%
1M Return
-0.36%
3M Return
-23.51%
6M Return
-3.99%
1Y Return
7.42%
Fundamentals
Market Cap ($ Mn)
3,027
PE Ratio
-
PB Ratio
4.59
PEG Ratio
-
ROE
-48.18%
ROCE
-50.13%
EPS (TTM)
$0.44
Investment Returns
1 Week
-9.85%
1 Month
-0.36%
3 Months
-23.51%
6 Months
-3.99%
9 Months
-4.09%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
3.6
Jun 26
17.8
Sep 26
Updates
4Nov
BTIG reiterates Buy on Denali Therapeutics with $39 target
BTIG analyst Thomas Shrader reiterated a Buy rating on Denali Therapeutics. The firm maintained its $39 price target for the stock. The rating action indicates stable analyst sentiment towards the company.
Q3 revenue of $17.778 million beat analyst estimates by 66.83%. Adjusted EPS of $(0.64) missed consensus estimate of $(0.53). Q4 revenue guidance of $30-$32 million exceeds analyst forecast of $22.659 million.
9 days ago
28Jul
Denali Therapeutics to report Q2 2026 results on Aug 6
Denali Therapeutics Inc. will report second quarter 2026 financial results on August 6, 2026. Management will host a conference call at 4:30 p.m. Eastern Time to discuss the results and business updates. The webcast will be available on the company's website.
3mo ago
17Jul
Denali offers natural fertilizer to cut farmer input costs
Denali provides a low-cost natural fertilizer alternative to help U.S. farmers manage rising input costs. An analysis shows savings of up to $246 per acre compared to synthetic fertilizers in key regions. The solution uses domestic organic materials, offering stable supply and soil health benefits.
3mo ago
16Jul
Deutsche Bank raises Denali Therapeutics target to $35
Deutsche Bank analyst David Hoang maintained a Buy rating on Denali Therapeutics and increased the price target to $35 from $31. This follows previous coverage by JP Morgan, which had an Overweight rating and a $29 price target on the NASDAQ-listed company.
3mo ago
10Jul
Denali Therapeutics highlights blood-brain barrier advances at AAIC 2026
Denali Therapeutics Inc. announced that CEO Ryan Watts, Ph.D., will deliver the opening plenary address at AAIC 2026, focusing on breakthroughs in blood-brain barrier delivery. The company highlighted its TransportVehicle platform and the progress of investigational therapies DNL628 and DNL921 for Alzheimer’s disease, with clinical data expected in 2027.
